Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Matutes E, Morilla R, Farahat N et al. Definition of acute biphenotypic leukemia. Haematologica 82(1), 64–66 (1997).
  Medline CASGoogle Scholar
• 2 Weinberg OK, Arber DA. Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia 24(11), 1844–1851 (2010).
  Medline CASGoogle Scholar
• 3 Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood 125(16), 2477–2485 (2015).
  Medline CASGoogle Scholar
• 4 Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 41(5), 483–493 (2008).
  Medline CASGoogle Scholar
• 5 Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103(3), 767–776 (2004).
  Medline CASGoogle Scholar
• 6 Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136(3), 334–342 (2012).
  Medline CASGoogle Scholar
• 7 Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets 4(7), 525–536 (2003).
  Medline CASGoogle Scholar
• 8 Swerdlow SH. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (4th Edition). IARC Press, Lyon, France (2008).
  Google Scholar
• 9 Topp MS, Gökbuget N, Stein AS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, Phase 2 study. Lancet Oncol. 16(1), 57–66 (2015). • Clinical trial that proved the efficacy of blinatumomab in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
  Medline CASGoogle Scholar
• 10 Topp MS, Gökbuget N, Zugmaier G et al. Long-term follow-up of hematologic relapse-free survival in a Phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26), 5185–5187 (2012).
  Medline CASGoogle Scholar
• 11 Topp MS, Gökbuget N, Zugmaier G et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32(36), 4134–4140 (2014).
  Medline CASGoogle Scholar
• 12 Topp MS, Kufer P, Gökbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29(18), 2493–2498 (2011).
  Medline CASGoogle Scholar
• 13 Klinger M, Brandl C, Zugmaier G et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119(26), 6226–6233 (2012).
  Medline CASGoogle Scholar
• 14 Zugmaier G, Topp MS, Alekar S et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 4, 244 (2014).
  Medline CASGoogle Scholar
• 15 Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol. Oncol. Clin. North Am. 15(1), 163–205 (2001).
  Medline CASGoogle Scholar
• 16 Stein A, Topp MS, Kantarjian H et al. Treatment with anti-CD19 BiTE blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic Leukemia (r/r ALL) postallogeneic hematopoietic stem cell transplantation. Presented at: 57th ASH Annual Meeting and Exposition 2015. Orlando, FL, USA, 4–8 December 2015. • Clinical trial that showed equivalent efficacy of blinatumomab in heavily treated ALL patients with prior allogeneic stem cell transplantation.
  Google Scholar
• 17 Ribera JM, Ferrer A, Ribera J, Genescà E. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. Onco Targets Ther. 8, 1567–1574 (2015).
  MedlineGoogle Scholar
• 18 Yannakou C, Came N, Bajel A, Juneja S. CD19 negative relapse in B-ALL treated with blinatumomab therapy: avoiding the trap. Blood 126(23), 4983–4983 (2015).
  Google Scholar
• 19 Diarrhea, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974–977 (2008). •• The first paper that showed the efficacy of blinatumomab in vitro.
  MedlineGoogle Scholar
• 20 Brandl C, Haas C, D'argouges S et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol. Immunother. 56(10), 1551–1563 (2007).
  Medline CASGoogle Scholar
• 21 Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J. Rheumatol. 22(7), 1281–1285 (1995).
  Medline CASGoogle Scholar
• 22 Gökbuget N, Kneba M, Raff T et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120(9), 1868–1876 (2012).
  MedlineGoogle Scholar
• 23 Teachey DT, Rheingold SR, Maude SL et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121(26), 5154–5157 (2013).
  Medline CASGoogle Scholar